Anika Therapeutics
Open enrollment with a later-stage pipeline tilt
According to ClinicalTrials.gov-derived indexes, Anika Therapeutics sits in the upper quartile of US sponsors by registered trial count (#2,411 of 15,742 sponsors by registered trial count).
Anika Therapeutics: 5 sponsored US clinical trials, 1 recruiting.
Anika Therapeutics sponsors 5 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 3 completed. 1 of these trials are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Defect of Articular Cartilage, with 1 trials.
Upper-quartile sponsor footprint
Anika Therapeutics sits in the upper quartile of the sponsor corpus (#2,411 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
5 total, page 1 of 1
Integrity Implant System Post Market Clinical Follow-Up Study
NCT06741527
HyaloFAST Trial for Repair of Articular Cartilage in the Knee
NCT02659215
Study of Cingal® and Triamcinolone Hexacetonide for the Relief of Knee Osteoarthritis Pain
NCT04231318
Safety Study of Cosmetic Tissue Augmentation in People of Color
NCT01147172
Safety and Effectiveness of Monovisc® Injection for Osteoarthritis of the Knee
NCT00653432
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 3 | 1 |
Therapeutic Areas
Where Anika Therapeutics enrollment is open (later-stage tilt)
1 recruiting of 5 indexed (20% open); 3 completed (60%).
Phase mix: 1 late (III/IV) vs 0 early (I/II) (later-stage heavy).
Top condition: Defect of Articular Cartilage (1 trial), 1 other listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Anika Therapeutics: open-pipeline peers nationwide
Peers matched on 5 registered trials and 20% open enrollment, not the therapeutic-area sidebar.
Anika Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 5 trials (± recruiting share)
- 4YouandMe · 5 trials · 0% recruiting
- Abbott Rapid Dx · 5 trials · 0% recruiting
- Access Business Group · 5 trials · 0% recruiting
- Acera Surgical · 5 trials · 20% recruiting
Sponsors near 20% open enrollment (± trial volume)
- Align Technology · 20% recruiting · 5 trials
- AltruBio · 20% recruiting · 5 trials
- Alvernia University · 20% recruiting · 5 trials
- Amazentis · 20% recruiting · 5 trials
Related
What to do with this Anika Therapeutics page
5 registered trials is a research-attention snapshot, not an endorsement of Anika Therapeutics or any single study.
- 1 of Anika Therapeutics's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Defect of Articular Cartilage is the condition Anika Therapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Defect of Articular Cartilage trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Anika Therapeutics pipeline card: 5 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.